Rezolute, Inc. Common Stock (NV)
RZLTRezolute, Inc. (RZLT) is a biotechnology company focused on developing treatments for metabolic and rare diseases. The company's portfolio includes therapies aimed at addressing diabetes, congenital hyperinsulinism, and other underserved conditions. Rezolute specializes in innovative drug formulations and has a pipeline of product candidates progressing through clinical development.
Company News
Pomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation following a significant stock price decline. The investigation was triggered by disappointing Phase 3 trial results from development partner Rezolute for the drug ersodetug, which failed to meet primary and secondary endpoints in treating congenital ...
Rezolute, Inc. shares collapsed approximately 85-90% on December 11, 2025, after the company's Phase 3 sunRIZE clinical trial for its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in treating congenital hyperinsulinism. The stock dropped from around $10.94 to an intraday low near $0.90, triggering Nasdaq volatil...
Rezolute's stock plummeted on December 11, 2025, following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug, a lead drug candidate for congenital hyperinsulinism. The study failed to meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events ...
Rezolute's stock dropped 90% after its Phase 3 trial for ersodetug failed to meet primary and secondary endpoints in treating hypoglycemia caused by hyperinsulinism, prompting a shareholder investigation.
Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds
